Get the Stockscreener App
265.82
2.04%
-5.54
Abbvie Inc stock is traded at $265.82, with a volume of 1.55M.
It is down -2.04% in the last 24 hours and up +6.85% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$271.36
Open:
$270.98
24h Volume:
1.55M
Relative Volume:
0.33
Market Cap:
$469.74B
Revenue:
$62.82B
Net Income/Loss:
$3.60B
P/E Ratio:
131.11
EPS:
2.0274
Net Cash Flow:
$19.98B
1W Performance:
+2.27%
1M Performance:
+6.85%
6M Performance:
+25.63%
1Y Performance:
+14.95%
1-Day Range:
$265.74
$271.61
1-Week Range:
$257.87
$274.94
52-Week Range:
$190.75
$274.94
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
265.82 | 469.74B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,141.28 | 1.02T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
252.72 | 609.03B | 97.93B | 21.04B | 17.80B | 8.6278 |
MRK
Merck Co Inc
|
139.57 | 344.34B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
141.21 | 268.40B | 54.66B | 13.58B | 16.05B | 7.0171 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Aug-05-26 | Upgrade | Erste Group | Hold → Buy |
| Apr-30-26 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3? - Zacks Investment Research
HSBC Raises AbbVie Price Target to $315 on Immunology Drug Label Expansions - NAI500
AbbVie (ABBV) Pays Out More Than It Earns. How Long Can That Hold? - Yahoo Finance
HSBC Thinks AbbVie Can Climb to $315. Here's the Bull Case in Plain English. - Yahoo Finance
AbbVie's Epkinly Could Be Preferred Frontline DLBCL Agent, UBS Says - marketscreener.com
Abbvie-Genmab Epkinly data signal first-line filing for DLBCL - BioWorld News
AbbVie stock cuts its Q3 EPS guidance to USD 3.730-3.770 - AD HOC NEWS
AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCL - Zacks Investment Research
UBS reiterates Abbvie stock rating on positive cancer trial data By Investing.com - Investing.com Canada
Should You Buy AbbVie Stock Before Oct. 30? - Yahoo Finance
AbbVie Rewarded Patient Investors but Punished Those Who Bought on Good News - Yahoo Finance
AbbVie Rewarded Patient Investors but Punished Those Who Bought on Good News - 24/7 Wall St.
Genmab jumps after positive trial of AbbVie-partnered lymphoma drug - Sharecast.com
IYH Beats IXJ on Returns While Global Fund Offers Higher Yield - The Motley Fool
BofA raises target for AbbVie stock from USD 282.00 to USD 289.00 - AD HOC NEWS
Strength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength? - Zacks Investment Research
A lymphoma drug combination cut the risk of worsening or death by 51% in a trial. - Stock Titan
Genmab, AbbVie blood cancer drug combo cuts risk of progression or death in late-stage study - Reuters
AbbVie (ABBV) Flags $216M IPR&D Expense Impacting Q3 and Full-Ye - GuruFocus
Why AbbVie (ABBV) Outpaced the Stock Market Today - Zacks Investment Research
Why AbbVie (ABBV) Outpaced the Stock Market Today - Yahoo Finance
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
An estimated $216M Q3 expense lowers AbbVie (ABBV)'s 2026 adjusted earnings outlook. - Stock Titan
Why I Think These Are the 2 Smartest Stocks to Buy With $5,000 in October - The Motley Fool
Better Dividend for Retirees: AbbVie vs. Merck - Yahoo Finance
Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma - GlobeNewswire Inc.
FDA Expands Eli Lilly's Blood Cancer Drug Label in First-Line Setting - Zacks Investment Research
AbbVie Announced Its 340B Rebate Pilot on October 2. Here’s What It Means for the Stock Before Vraylar’s 2027 Medicare Price Cut - Yahoo Finance
Better Healthcare ETF: Vanguard's Broad VHT vs. the iShares Biotechnology-Focused IBB - The Motley Fool
AbbVie Just Won FDA Approval for a Once-Daily Parkinson's Pill. Here's Why It Matters More Than You Think. - Yahoo Finance
Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP - The Motley Fool
How to Create a Million-Dollar Stock Portfolio - Zacks Investment Research
AbbVie joins US government pilot to test drug discount rebates - Reuters
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise? - Zacks Investment Research
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - Zacks Investment Research
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell? - Zacks Investment Research
AbbVie Stock: Buy, Sell, or Hold in October? - Yahoo Finance
AbbVie Stock: Buy, Sell, or Hold in October? - The Motley Fool
Novo Nordisk Gives Uninspiring Outlook - The Motley Fool
AbbVie (ABBV) Falls More Steeply Than Broader Market: What Investors Need to Know - Zacks Investment Research
Defensive Dividends: 3 Companies Investors Can Rely On - Zacks Investment Research
AbbVie (NYSE:ABBV) Wins Juvmo Approval for Parkinson's Disease - Kalkine Media
AbbVie Stock Drops Although Juvmo Wins Parkinson's Approval - Yahoo Finance
AbbVie Stock Drops Although Juvmo Wins Parkinson's Approval - GuruFocus
AbbVie Wins FDA Nod for New Parkinson's Disease Drug Juvmo - Yahoo Finance
AbbVie Wins FDA Nod for New Parkinson's Disease Drug Juvmo - Zacks Investment Research
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Abbvie Inc Stock (ABBV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER |
Aug 14 '26 |
Sale |
250.00 |
32,710 |
8,177,500 |
74,430 |
| NICHOLAS DONOGHOE | Officer |
Aug 14 '26 |
Proposed Sale |
250.00 |
32,710 |
8,177,500 |
0 |
| ROBERT J ALPERN | Director |
May 26 '26 |
Proposed Sale |
214.00 |
13,000 |
2,781,991 |
0 |
| Purdue David Ryan | SVP, Controller |
Mar 04 '26 |
Sale |
233.56 |
5,230 |
1,221,519 |
2,654 |
| David R. Purdue | Officer |
Mar 04 '26 |
Proposed Sale |
233.56 |
5,230 |
1,221,519 |
0 |
| Siatis Perry C | EVP, GC AND SECRETARY |
Mar 02 '26 |
Sale |
234.39 |
18,668 |
4,375,549 |
4,619 |
| PERRY C SIATIS | Officer |
Mar 02 '26 |
Proposed Sale |
234.39 |
18,668 |
4,375,585 |
0 |
| Siatis Perry C | EVP, GC AND SECRETARY |
Feb 25 '26 |
Option Exercise |
172.62 |
22,381 |
3,863,458 |
60,518 |
| Siatis Perry C | EVP, GC AND SECRETARY |
Feb 25 '26 |
Sale |
230.00 |
22,381 |
5,147,630 |
38,137 |
| PERRY C SIATIS | Officer |
Feb 25 '26 |
Proposed Sale |
230.00 |
22,381 |
5,147,630 |
0 |
2.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):